GRI (GRI) director granted 5,994 options at $1.41; 4,044 vested immediately
GRI Bio, Inc. director David Charles Baker received a stock option grant on 08/26/2025 allowing purchase of 5,994 shares of common stock at an exercise price of $1.41 per share.
Rhea-AI Filing Summary
GRI Bio, Inc. director David Charles Baker received a stock option grant on 08/26/2025 allowing purchase of 5,994 shares of common stock at an exercise price of $1.41 per share. Of the total, 4,044 options vested immediately on the grant date; the remaining 1,950 options vest in four substantially equal quarterly installments and will be fully vested on the one-year anniversary of the grant. The options expire on 08/26/2035. Following the grant, Mr. Baker directly beneficially owns 5,994 underlying shares from the option award.
Positive
- Immediate alignment: 4,044 options vested in full on the grant date, creating immediate officer alignment with shareholders
- Clear vesting schedule: Remaining 1,950 options vest in four substantially equal quarterly installments, completing within one year
- Long option term: Expiration in 2035 provides extended upside potential for the awardee
Negative
- None.
Insights
TL;DR: A routine director stock option grant: immediate partial vesting plus short-term continued vesting, long-dated expiry may align incentives.
The grant awards 5,994 options at a $1.41 strike with immediate vesting of 4,044 and the remainder vesting over four quarters, completing on the first anniversary. The option term extends to 2035, providing long-dated upside but with most economic exposure concentrated after near-term vesting. This is a standard equity-based compensation event for a director and does not, by itself, alter outstanding capital structure or report other transactions.
TL;DR: Compensation-related disclosure shows a director-focused equity award with phased vesting; it is a governance routine rather than a material corporate change.
The filing documents the relationship (reporting person is a director) and the specific vesting schedule: significant immediate vesting signals retention or alignment intent, while quarterly vesting of the remainder encourages continued service through the first year. No transfers, sales, or exercises are reported. This is a standard, non-transactional disclosure under Section 16 reporting rules.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 5,994 | $0.00 | $0.00 |
Footnotes (1)
- F1. Options to purchase 4,044 shares vested in full upon the date of grant and options to purchase 1,950 shares will vest in four substantially equal quarterly installments such that the stock option is fully vested on the first anniversary of the date of grant.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GRI (GRI) disclose in this Form 4 filing?
How many options vested immediately for David Charles Baker?
What is the vesting schedule for the remaining options?
When do the options expire and what is the exercise price?
Does the Form 4 show any sales or dispositions by the reporting person?
AI-generated analysis. How Rhea-AI works. Not financial advice.